Biosimilars Get Bespoke Service: EMA To Pilot Tailored Scientific Advice
Executive Summary
Quality data will be focus of ‘extra advice’ offered by European Medicines Agency’s pilot, which will suggest directions for sponsors’ next steps but stop short of formal data evaluation.
You may also be interested in...
EMA’s Pilot On Bespoke Scientific Advice For Biosimilars Attracts Monoclonal Antibody Makers
Monoclonal antibody developers are showing interest in the European Medicines Agency’s pilot project that is offering bespoke scientific advice on biosimilars.
EMA’s Pilot On Bespoke Scientific Advice For Biosimilars Attracts Monoclonal Antibody Makers
Monoclonal antibody developers are showing interest in the European Medicines Agency’s pilot project that is offering bespoke scientific advice on biosimilars.
Biosimilars In EU: From 'New Mess' To Beacon For Safety
Finnish Medicines Agency's Ekman says neither regulators nor industry knew what to do when the biosimilars regulatory framework was first introduced, but there haven't been any differences in adverse events between biosimilars and their reference products.